Upadacitinib for Severe Alopecia Areata in Children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, phase 3 trial compares different doses of upadacitinib to placebo in pediatric participants with severe alopecia areata. Eligible participants have SALT hair loss of 50% or more on the scalp and no regrowth in 6 months. The study aims to determine safety and the best dose to improve hair restoration over time. Enrolled participants will receive either upadacitinib or a placebo and will be monitored for responses and adverse events. The trial is sponsored by AbbVie and conducted at multiple dermatology centers in the United States.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must have a diagnosis of severe alopecia areata with SALT score \>= 50 scalp hair loss at Screening and Baseline
* No spontaneous scalp hair regrowth over the past 6 months
* Participants will have current episode of alopecia areata of less than 8 years

Exclusion Criteria:

* Participants must not have a current diagnosis of primarily diffuse type of alopecia areata
* Participants must not have a diagnosis of other types of alopecia that would interfere with evaluation of alopecia areata, including but not limited to female pattern hair loss, male pattern hair loss (androgenetic alopecia) Stage III or greater, traction alopecia, lichen planopilaris, discoid lupus, frontal fibrosing alopecia, central centrifugal cicatricial alopecia, folliculitis decalvans, trichotillomania, and telogen effluvium
* Participants must not have a diagnosis of other types of inflammatory scalp, eyebrow, or eyelash disorders that would interfere with evaluation of alopecia areata, including but not limited to seborrheic dermatitis, scalp psoriasis, AD, and tinea capitis

Where it's running

• Dermatology Research Associates - Los Angeles /ID# 282821
  Los Angeles, California, United States Recruiting
• Pediatric Skin Research - Miami /ID# 283281
  Miami, Florida, United States Recruiting
• Ada West Research /ID# 283063
  Meridian, Idaho, United States Recruiting
• Dawes Fretzin- Indianapolis /ID# 283498
  Indianapolis, Indiana, United States Recruiting
• Skin Specialists /ID# 283358
  Omaha, Nebraska, United States Recruiting
• Dermatologists of Southwestern Ohio (DSWO) /ID# 282818
  Fairborn, Ohio, United States Recruiting

Study contacts

• Study coordinator: Abbvie Call Center
• Email: abbvieclinicaltrials@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

• Upadacitinib for Eosinophilic Esophagitis in adults not responding to standard therapy

  This study tests whether upadacitinib, taken with topical corticosteroids, can reduce disease activity in adults with eosinophilic esophagitis who still have symptoms.

  Recruiting Phase 2 University of North Carolina, Chapel Hill · Chapel Hill, North Carolina and 1 other locations · NCT07588568

• Safety and body handling of IBI3013 after single and multiple doses in healthy adults and men with active non-segmental vitiligo or severe alopecia areata

  This trial tests whether IBI3013 is safe and how the body processes it in healthy adults and in men with active non-segmental vitiligo or severe alopecia areata.

  Recruiting Phase 1 Innovent Biologics (Suzhou) Co. Ltd. · Shanghai, Shanghai Municipality · NCT07554222

• Upadacitinib versus infliximab for second-line treatment of acute severe ulcerative colitis

  This trial will see if upadacitinib or infliximab works better to induce remission in adults with acute severe ulcerative colitis who need second-line therapy.

  Recruiting at 4 sites Phase 4 Xijing Hospital of Digestive Diseases · Ankang, Shaanxi and 3 other locations · NCT07550673

• Upadacitinib versus corticosteroids for first-line treatment of acute severe ulcerative colitis

  This test will see if upadacitinib works as well as corticosteroids to induce remission in adults with acute severe ulcerative colitis.

  Recruiting at 4 sites Phase 4 Xijing Hospital of Digestive Diseases · Ankang, Shaanxi and 3 other locations · NCT07546097

• TNFi plus low-dose upadacitinib versus TNFi dose intensification for Crohn's disease with suboptimal response

  This trial tests whether adding low-dose upadacitinib to a standard TNF blocker helps adults with moderate-to-severe Crohn's disease who haven't responded well to standard-dose infliximab or adalimumab, compared with increasing the TNFi dose.

  Recruiting Phase 4 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07510191

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.